Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, routine-filing, pharmaceuticals
TL;DR
Tonix Pharma filed a routine 8-K on 7/10/25. Check for specifics.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on July 10, 2025, reporting on other events and financial statements. The company, incorporated in Nevada, is based in Chatham, New Jersey, and operates in the pharmaceutical preparations industry. This filing does not appear to disclose specific material events or financial figures beyond its routine reporting nature.
Why It Matters
This 8-K filing indicates routine corporate reporting by Tonix Pharmaceuticals. Investors should review the specific items disclosed within the filing for any material updates.
Risk Assessment
Risk Level: low — The filing appears to be a standard 8-K with no immediately apparent material adverse events or significant financial disclosures.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- July 10, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of Incorporation
- Chatham, New Jersey (location) — Principal executive offices
- 26 Main Street, Suite 101 (address) — Business and Mail Address
FAQ
What specific 'Other Events' are reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported in the 8-K, only that it is an item covered by the filing.
What is the primary business of Tonix Pharmaceuticals Holding Corp.?
Tonix Pharmaceuticals Holding Corp. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
When was Tonix Pharmaceuticals Holding Corp. incorporated?
The company was incorporated in Nevada.
What is the principal executive office address for Tonix Pharmaceuticals?
The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.
What is the filing date of this 8-K report?
The report was filed as of July 10, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).